EXEL - Exelixis Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

5.103B

Cash

1.313B

Avg Qtr Burn

N/A

Short % of Float

2.59%

Insider Ownership

2.42%

Institutional Own.

92.26%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CABOMETYX (cabozantinib) Details Solid tumor/s, Renal cell carcinoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COTELLIC (cobimetinib) Details Metastatic melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COMETRIQ (cabozantinib) Details Metastatic MTC (Medullary Thyroid Cancer)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CABOMETYX (cabozantinib)+atezolizumab Details Solid tumor/s, Cancer, Castration-resistant prostate cancer Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib (XL092) Details Solid tumor/s, Colorectal cancer , Cancer	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cabozantinib + Nivolumab + Ipilimumab Details Solid tumor/s, Cancer, Kidney cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanzalintinib (XL092) Details Solid tumor/s, Colorectal cancer , Cancer	Phase 1b Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CBX-12 (topoisomerase I inhibition) Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.